Selecta Biosciences Announces Three Presentations at the Upcoming 24th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)

Apr 29, 2021

WATERTOWN, Mass., April 29, 2021 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced three upcoming presentations at the 24th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT), to be held virtually from May 11-14, 2021. These presentations further demonstrate the potential of Selecta’s ImmTOR platform to mitigate AAV immunogenicity and enable redosing of gene therapy treatments for various genetic disorders.

“We are excited to present data on ImmTOR’s potential to address current limitations in the gene therapy field including efficacy, safety and durability at ASGCT,” said Dr. Takashi Kei Kishimoto, Ph.D., chief scientific officer of Selecta. “The results to be presented continue to highlight ImmTOR’s ability to enable redosing of AAV-based gene therapies and prevent the production of AAV-specific neutralizing antibodies (NAbs) in vivo. As many gene therapies will be targeted to pediatric patients, maintaining therapeutic activity is of the utmost importance to families of patients with genetic disorders, a concern that we believe ImmTOR has the potential to solve moving forward.”

Oral Presentation:
Presentation Title: Coadministration of AAV Expressing MDR3 (VTX-803) and ImmTOR Allows for Vector Re-Administration to Treat Progressive Familial Intrahepatic Cholestasis Type 3 (PFIC3) in Juvenile Abcb4-/- Mice
Session Title: Gene Therapy for Inborn Errors of Metabolism
Abstract Number: 29
Presenter: Nicholas D. Weber, Ph.D.
Presentation Date and Time: Tuesday, May 11, 2021 5:30 p.m. ET

An oral presentation from scientists at Vivet Therapeutics will highlight the potential of ImmTOR to enable repeated intravenous administration of liver-directed AAV vector carrying human ABCB4 cDNA (VTX-803) in a juvenile mouse model of progressive familial intrahepatic cholestasis type 3 (PFIC3). These data highlight the power of redosing AAV gene therapy with ImmTOR to sustain therapeutic efficacy in juvenile animals.

Digital Poster Presentations:
Presentation Title: ImmTOR Nanoparticles Promote Survival and Enable Repeat Gene Therapy of MMUT-Deficient Mice with Maternally-Transferred Anti-AAV Antibodies
Session Title: Metabolic, Storage, Endocrine, Liver and Gastrointestinal Diseases
Abstract Number: 483
Presenter: Petr Ilyinskii, Ph.D.
Presentation Date and Time: Tuesday, May 11, 2021 8 a.m. ET

Results presented in this poster show the potential of a combination of ImmTOR and AAV-based gene therapy vector to mitigate the detrimental impact of maternally-transferred anti-AAV antibodies in a mouse model of methylmalonic acidemia (MMA).

Presentation Title: ImmTOR Nanoparticles Enhance the Level and Durability of AAV Transgene Expression after Initial Dosing and Mitigate the Formation of Neutralizing Antibodies in Nonhuman Primates
Session Title: Immunological Aspects of Gene Therapy and Vaccines
Abstract Number: 761
Presenter: Takashi K. Kishimoto, Ph.D.
Presentation Date and Time: Tuesday, May 11, 2021 8 a.m. ET

This poster presents data from a large NHP study that builds upon previous data showing that tolerogenic ImmTOR nanoparticles can selectively mitigate anti-AAV T and B cell responses to enable vector redosing in mice and small nonhuman primates (NHP). These results indicate that ImmTOR may enhance the level and durability of transgene expression after initial treatment of AAV vector while inhibiting the formation of neutralizing antibodies.

Following the conference, the three presentations will be available in the Resources section of Selecta’s website at

About Selecta Biosciences, Inc.
Selecta Biosciences Inc. (NASDAQ: SELB) is leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses. With a proven ability to induce tolerance to highly immunogenic proteins, ImmTOR has the potential to amplify the efficacy of biologic therapies, including redosing of life-saving gene therapies, as well as restore the body’s natural self-tolerance in autoimmune diseases. The company’s first program aimed at addressing immunogenicity to AAV gene therapies is expected to enter clinical trials in early 2021 in partnership with AskBio for the treatment of methylmalonic acidemia (MMA), a rare metabolic disorder. A wholly-owned program focused on addressing IgA nephropathy driven by ImmTOR and a therapeutic enzyme is also in development among additional product candidates. Selecta recently licensed its Phase 3 clinical product candidate, SEL-212, in chronic refractory gout to Sobi. For more information, please visit

Selecta Forward-Looking Statements
Any statements in this press release about the future expectations, plans and prospects of Selecta Biosciences, Inc. (“the company”), including without limitation, statements regarding the unique proprietary technology platform of the company, and the unique proprietary platform of its partners, the potential of ImmTOR to enable re-dosing of AAV gene therapy, the potential treatment applications of product candidates utilizing the ImmTOR platform in areas such as gene therapy, the ability of the Company and AskBio to develop gene therapy products using ImmTOR and AskBio’s technology, the novelty of treatment paradigms that the Company is able to develop, whether the observations made in non-human primate study subjects will translate to studies performed with human beings, the potential of any therapies developed by the company and AskBio to fulfill unmet medical needs, the company’s plan to apply its ImmTOR technology platform to a range of biologics for rare and orphan genetic diseases, the potential of the company’s intellectual property to enable repeat administration in gene therapy product candidates and products, the ability to re-dose patients and the potential of ImmTOR to allow for re-dosing, the potential to safely re-dose AAV, the ability to restore transgene expression, the potential of the ImmTOR technology platform generally and the company’s ability to grow its strategic partnerships,  and other statements containing the words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “hypothesize,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “would,” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including, but not limited to, the following: the uncertainties inherent in the initiation, completion and cost of clinical trials including proof of concept trials, including the uncertain outcomes, the availability and timing of data from ongoing and future clinical trials and the results of such trials, whether preliminary results from a particular clinical trial will be predictive of the final results of that trial or whether results of early clinical trials will be indicative of the results of later clinical trials, the ability to predict results of studies performed on human beings based on results of studies performed on non-human primates, the unproven approach of the company’s ImmTOR technology, potential delays in enrollment of patients, undesirable side effects of the company’s product candidates, its reliance on third parties to manufacture its product candidates and to conduct its clinical trials, the company’s inability to maintain its existing or future collaborations, licenses or contractual relationships, its inability to protect its proprietary technology and intellectual property, potential delays in regulatory approvals, the availability of funding sufficient for its foreseeable and unforeseeable operating expenses and capital expenditure requirements, the company’s recurring losses from operations and negative cash flows from operations raise substantial doubt regarding its ability to continue as a going concern, substantial fluctuation in the price of its common stock, and other important factors discussed in the “Risk Factors” section of the company’s most recent Quarterly Report on Form 10-Q, and in other filings that the company makes with the Securities and Exchange Commission. In addition, any forward-looking statements included in this press release represent the company’s views only as of the date of its publication and should not be relied upon as representing its views as of any subsequent date. The company specifically disclaims any intention to update any forward-looking statements included in this press release.

For Investors:
Bruce Mackle
LifeSci Advisors, LLC

For Media:
Meredith Sosulski, Ph.D.
LifeSci Communications, LLC

Primary Logo

Source: Selecta Biosciences, Inc.